Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

MR1-RESTRICTED T CELLS

‘Bohemian Rhapsody’ of MR1T cells

Nature Immunology volume 21, pages 108–110 (2020)Cite this article

Subjects

A T cell recognizing the MHC class I–related molecule MR1, expressed by a wide range of cancer cell types, might have great potential for adoptive cell therapy in cancer.

Like ‘Bohemian Rhapsody’, a kind of mock opera outside the norm of rock songs, which only became famous with time, MHC class I–related molecule–restricted T cells (MR1T cells) appeared outside the box and are now being appreciated for their functions and great potential in cancer immunotherapy. In the current issue of Nature Immunology, Crowther et al.1 describe an MR1-restricted T cell clone with possible importance in translational anti-cancer responses.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Broad tumor recognition by MR1T cells.

References

  1. Crowther, M. D. et al. Nat. Immunol. https://doi.org/10.1038/s41590-019-0578-8 (2019).

    Article  Google Scholar 

  2. Porcelli, S., Yockey, C. E., Brenner, M. B. & Balk, S. P. J. Exp. Med. 178, 1–16 (1993).

    Article  CAS  Google Scholar 

  3. Tilloy, F. et al. J. Exp. Med. 189, 1907–1921 (1999).

    Article  CAS  Google Scholar 

  4. Treiner, E. et al. Nature 422, 164–169 (2003).

    Article  CAS  Google Scholar 

  5. Reantragoon, R. et al. J. Exp. Med. 210, 2305–2320 (2013).

    Article  CAS  Google Scholar 

  6. Gold, M. C. et al. J. Exp. Med. 211, 1601–1610 (2014).

    Article  CAS  Google Scholar 

  7. Lepore, M. et al. Nat. Commun. 5, 3866 (2014).

    Article  Google Scholar 

  8. Kjer-Nielsen, L. et al. Nature 491, 717–723 (2012).

    Article  CAS  Google Scholar 

  9. Corbett, A. J. et al. Nature 509, 361–365 (2014).

    Article  CAS  Google Scholar 

  10. Meermeier, E. W. et al. Nat. Commun. 7, 12506 (2016).

    Article  CAS  Google Scholar 

  11. Gherardin, N. A. et al. Immunity 44, 32–45 (2016).

    Article  CAS  Google Scholar 

  12. Koay, H. F. et al. Nat. Commun. 10, 2243 (2019).

    Article  Google Scholar 

  13. Lepore, M. et al. eLife 6, e24476 (2017).

    Article  Google Scholar 

  14. Lepore, M., Mori, L. & De Libero, G. Front. Immunol. 9, 1365 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland

    Lucia Mori & Gennaro De Libero

Authors
  1. Lucia Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gennaro De Libero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucia Mori.

Ethics declarations

Competing interests

The University of Basel has filed a patent on MR1T cells.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mori, L., De Libero, G. ‘Bohemian Rhapsody’ of MR1T cells. Nat Immunol 21, 108–110 (2020). https://doi.org/10.1038/s41590-019-0588-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-019-0588-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer